[1] United Nations Office on Drugs and Crime. World drug report 2023. https://www.unodc.org/res/WDR-2023/WDR23_Exsum_fin_DP.pdf. [2024-04-15].
[2] United Nations Office on Drugs and Crime. World drug report 2013. https://www.unodc.org/unodc/secured/wdr/wdr2013/World_Drug_Report_2013.pdf. [2024-04-15].
[3] Volkow ND, Baler RD, Compton WM, Weiss SRB. Adverse health effects of marijuana use. N Engl J Med 2014;370(23):2219 − 27. https://doi.org/10.1056/NEJMra1402309CrossRef
[4] Zhu H, Wu LT. Trends and correlates of cannabis-involved emergency department visits: 2004 to 2011. J Addict Med, 2016;10(6):429 − 36. https://doi.org/10.1097/ADM.0000000000000256CrossRef
[5] World Health Organization. The health and social effects of nonmedical cannabis use. https://www.who.int/publications-detail-redirect/9789241510240. [2024-04-15].
[6] Pacula RL, Ringel J, Dobkin C, Truong K. The incremental inpatient costs associated with marijuana comorbidity. Drug Alcohol Depend, 2008;92(1-3):248 − 57. https://doi.org/10.1016/j.drugalcdep.2007.08.011CrossRef
[7] Samples H, Levy NS, Bruzelius E, Segura LE, Mauro PM, Boustead AE, et al. Association between legal access to medical cannabis and frequency of non-medical prescription opioid use among U.S. adults. Int J Ment Health Addict, 2023:1 − 14. http://dx.doi.org/10.1007/s11469-023-01191-y.
[8] Mennis J, Stahler GJ. Adolescent treatment admissions for marijuana following recreational legalization in Colorado and Washington. Drug Alcohol Depend, 2020;210:107960. https://doi.org/10.1016/j.drugalcdep.2020.107960CrossRef
[9] Maciver B. Cannabis legalization world map: UPDATED. https://www.cannabisbusinesstimes.com/article/cannabis-legalization-world-map/. [2024-04-15].
[10] Kilmer JR, Rhew IC, Guttmannova K, Fleming CB, Hultgren BA, Gilson MS, et al. Cannabis use among young adults in Washington State after legalization of nonmedical cannabis. Am J Public Health 2022;112(4):638 − 45. https://doi.org/10.2105/AJPH.2021.306641CrossRef
[11] Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ, 2021;372:n71. https://doi.org/10.1136/bmj.n71CrossRef
[12] JBI. Checklist for prevalence studies. https://jbi.global/sites/default/files/2020-08/Checklist_for_Prevalence_Studies.pdf. [2024-04-15].
[13] Thorlund K, Imberger G, Johnston BC, Walsh M, Awad T, Thabane L, et al. Evolution of heterogeneity (I2) estimates and their 95% confidence intervals in large meta-analyses. PLoS One, 2012;7(7):e39471. https://doi.org/10.1371/journal.pone.0039471CrossRef
[14] Compton WM, Han B, Hughes A, Jones CM, Blanco C. Use of marijuana for medical purposes among adults in the United States. JAMA, 2017;317(2):209 − 11. https://doi.org/10.1001/jama.2016.18900CrossRef
[15] Yu B, Chen XG, Chen XF, Yan H. Marijuana legalization and historical trends in marijuana use among US residents aged 12-25: results from the 1979-2016 national survey on drug use and health. BMC Public Health, 2020;20(1):156. https://doi.org/10.1186/s12889-020-8253-4CrossRef
[16] Tominaga M, Kawakami N, Ono Y, Nakane Y, Nakamura Y, Tachimori H, et al. Prevalence and correlates of illicit and non-medical use of psychotropic drugs in Japan. Soc Psychiatry Psychiatr Epidemiol 2009;44(9):777 − 83. https://doi.org/10.1007/s00127-009-0499-1CrossRef
[17] Chawla D, Yang YC, Desrosiers TA, Westreich DJ, Olshan AF, Daniels JL. Past-month cannabis use among U.S. individuals from 2002-2015: an age-period-cohort analysis. Drug Alcohol Depend, 2018;193:177-82. http://dx.doi.org/10.1016/j.drugalcdep.2018.05.035.
[18] Tkalić RG, Miletić GM, Sakoman S. Prevalence of substance use among the general population: situation in Croatia and comparison with other European countries. Društvena Istraživanja 2013;22(4):557-8. http://dx.doi.org/10.5559/di.22.4.01.
[19] Shi YY, Lenzi M, An RP. Cannabis liberalization and adolescent cannabis use: a cross-national study in 38 countries. PLoS One, 2015;10(11):e0143562. https://doi.org/10.1371/journal.pone.0143562CrossRef